Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.

Published on Jan 8, 2021in Journal of Clinical Medicine3.303
· DOI :10.3390/JCM10020200
Alexander T. Cohen (Guy's and St Thomas' NHS Foundation Trust), Alexander T. Cohen59
Estimated H-index: 59
(Guy's and St Thomas' NHS Foundation Trust)
+ 6 AuthorsXuemei Luo22
Estimated H-index: 22
(Pfizer)
Sources
Abstract
This study integrated 5 United States healthcare claims databases to evaluate the risk of recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients who initiated apixaban vs. warfarin, stratified by obesity. Obese and morbidly obese patients were identified based on diagnosis codes. Stabilized inverse probability treatment weighting (IPTW) was conducted to balance observed patient characteristics between treatment cohorts. An interaction analysis was conducted to evaluate treatment effects of apixaban vs. warfarin according to obesity status. Cox proportional hazard models were used to evaluate the risk of recurrent VTE and MB among IPTW weighted obese and morbidly obese patients. A total of 112,024 non-obese patients and 43,095 obese patients were identified, of whom 19,751 were morbidly obese. When stratified by obesity status post-IPTW, no significant interactions were observed for effects of apixaban vs. warfarin on recurrent VTE or MB (interaction p > 0.10). Among IPTW obese and morbidly obese patients, apixaban was associated with a significantly lower risk of recurrent VTE (obese: 0.73 [0.64–0.84]; morbidly obese: 0.65 [0.53–0.80]) and MB (obese: 0.73 [0.62–0.85]; morbidly obese: 0.68 [0.54–0.86]) as compared with warfarin. In this large sample of obese and morbidly obese VTE patients, apixaban had a significantly lower risk of recurrent VTE and MB vs. warfarin.
📖 Papers frequently viewed together
23 Citations
201717.54Blood
3 Authors (Yun Choi, ..., Henny H. Billett)
10 Citations
References32
Newest
#1Alexander T. Cohen (Guy's and St Thomas' NHS Foundation Trust)
#1Alexander T. Cohen (Guy's and St Thomas' NHS Foundation Trust)H-Index: 59
Last. Xuemei Luo (Pfizer)H-Index: 22
view all 10 authors...
Background This study primarily evaluates the risk of recurrent venous thromboembolism (VTE) and major bleeding (MB) among patients with VTE and active cancer prescribed apixaban, low-molecular-weight heparin (LMWH), or warfarin, with claims data. Methods Four U.S. commercial insurance claims databases were used to identify patients with VTE and active cancer who initiated apixaban, LMWH, or warfarin within 30 days following the first VTE event. Stabilized inverse-probability treatment weighting...
4 CitationsSource
#1Waldemar E. Wysokinski (Mayo Clinic)H-Index: 29
#2David A. Froehling (Mayo Clinic)H-Index: 14
Last. Ana I. Casanegra (Mayo Clinic)H-Index: 9
view all 12 authors...
OBJECTIVES To investigate the association of extremes in body weight EBW and outcomes in patients with acute venous thromboembolism (VTE), recurrent VTE, major bleeding, and clinically relevant non-major bleeding were compared between patients with body weight 120 kg. METHODS Consecutive patients enrolled in the Mayo Clinic VTE Registry (03/28/2013-8/31/2019) with acute VTE were followed prospectively. Patient status was assessed in person, by mailing a written questionnaire, or by a scripted ph...
6 CitationsSource
#1Kelly L. Covert (ETSU: East Tennessee State University)H-Index: 4
#2Donald L Branam (South College)H-Index: 1
PURPOSE: To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations. SUMMARY: The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and e...
4 CitationsSource
#1James C. Coons (University of Pittsburgh)H-Index: 14
#2Lauren Albert (University of Pittsburgh)H-Index: 1
Last. Carlo J. Iasella (University of Pittsburgh)H-Index: 7
view all 4 authors...
STUDY OBJECTIVE: Studies on the use of direct oral anticoagulants (DOACs) in obese patients are limited. Current guidelines advise against DOAC use in patients with a body weight more than 120 kg or body mass index higher than 40 kg/m(2) . Therefore, the aim of this study was to evaluate the effectiveness and safety of DOACs versus warfarin for the treatment of acute venous thromboembolism (VTE) in obese patients. DESIGN: Retrospective matched cohort study. SETTING: Integrated delivery system of...
22 CitationsSource
#1Rahul JainH-Index: 2
#2Anna WatzkerH-Index: 1
Last. Joseph MenzinH-Index: 30
view all 8 authors...
AbstractObjective: To evaluate the validity of diagnosis codes for identifying obesity and morbid obesity among newly treated nonvalvular atrial fibrillation (NVAF) patients.Methods: An integrated ...
8 CitationsSource
#1Derek WeyckerH-Index: 37
#2Gail Wygant (BMS: Bristol-Myers Squibb)H-Index: 16
Last. Alexander T. CohenH-Index: 59
view all 10 authors...
In the phase 3 trial Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy, apixaban was noninferior to enoxaparin, overlapped and followed by warfarin, in the treatment of venous thromboembolism (VTE) with significantly less bleeding; in a real-world evaluation, risks for bleeding and recurrent VTE were lower with apixaban vs warfarin plus parenteral anticoagulant (PAC) bridge therapy. The present study extends this research by comparing outcom...
3 CitationsSource
#1Theodore LeeH-Index: 1
#2Sharon Pan (Pfizer)H-Index: 10
Last. Bushra S Ilyas (Pfizer)H-Index: 1
view all 4 authors...
1 CitationsSource
#1Patrick Hlavacek (Pfizer)H-Index: 5
#2Jennifer D Guo (BMS: Bristol-Myers Squibb)H-Index: 2
Last. Robert D. McBane (Mayo Clinic)H-Index: 51
view all 10 authors...
Objective: To compare safety, effectiveness, and healthcare costs of major bleeding (MB), clinically relevant non-major (CRNM) bleeding, recurrent venous thromboembolism (VTE), and all-caus...
4 CitationsSource
#1Margarita Kushnir (Albert Einstein College of Medicine)H-Index: 4
#2Yun Choi (NYU: New York University)H-Index: 2
Last. Henny H. Billett (Albert Einstein College of Medicine)H-Index: 23
view all 8 authors...
Summary Background Because studies of direct oral anticoagulants in patients with venous thromboembolism and non-valvular atrial fibrillation have had minimal representation of morbidly obese patients (ie, body-mass index [BMI] ≥40 kg/m 2 ), their efficacy and safety in this population are unclear. We investigated whether apixaban and rivaroxaban are as effective and safe as warfarin in morbidly obese patients. Methods We did a single-centre, retrospective analysis of chart data for all adult pa...
54 CitationsSource
#1Stephan Moll (UNC: University of North Carolina at Chapel Hill)H-Index: 30
#2Daniel J. Crona (UNC: University of North Carolina at Chapel Hill)H-Index: 14
Last. Karlyn Martin (NU: Northwestern University)H-Index: 8
view all 3 authors...
15 CitationsSource
Cited By2
Newest
#1Karlyn Martin (NU: Northwestern University)H-Index: 8
Last. Stephan Moll (UNC: University of North Carolina at Chapel Hill)H-Index: 30
view all 6 authors...
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and prevention in patients with obesity, including phase 3, phase 4, meta-analyses, and pharmacokinetic and pharmacodynamics studies. In addition, we reviewed available data regarding DOACs in bariatric surgery. ...
Source
#1Margaret M. Buck (Duquesne University)
#2Alexa M. Haddon (Duquesne University)
Last. Courtney A Montepara (Duquesne University)
view all 9 authors...
BACKGROUND AND OBJECTIVE Rivaroxaban and apixaban are direct oral anticoagulants increasing in popularity as convenient alternatives to warfarin. However, current guidelines recommend against use in patients with a BMI > 40 kg/m2 or bodyweight > 120 kg unless drug-specific levels are measured, which may not be feasible across all clinical practices. Accordingly, the objective of this study was to broadly examine literature evaluating the clinical outcomes of rivaroxaban and/or apixaban in patien...
Source